Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir

Abstract

Introduction: Viral hepatitis B is a major public health problem worldwide. The aim of this study was to evaluate the clinico-biological parameters in patients with chronic hepatitis B on Tenofovir. Patients and method: This was a cross-sectional study with retrospective data collection from April 1, 2019 to March 31, 2021, i.e. two years. Patients aged at least 15 years, regardless of sex, with a complete follow-up file were included. Results: A total of 920 files were evaluated, of which 145 met the inclusion criteria, i.e. a frequency of 15.76%. A male predominance was found (sex ratio 2.62). The average age was 33.24 years with extremes of 17 and 63 years. Students were more represented (36.6%). Incidental discovery was the most frequent mode (29.7%). Asthenia was the most frequent clinical manifestation (28.27%). Cytolysis was found in 82.76% of cases at the start of treatment. Creatinine levels were normal in most cases. HBV DNA was > 2000 IU/ml in 92.41% of cases. Abdominal ultrasound was normal in 51.25% of cases. Biological fibrosis scores (APRI and FIB-4) were used in almost one third of patients. The evolution was marked by a virological response of 82.35% at the 12th month and a normalization of transaminases in 91.6% of cases. Conclusion: Viral hepatitis B, a public health problem, is frequent among young people in our context. Tenofovir, effective, allows to obtain a significant virological response and a normalization of transaminases.